Angle PLC Patent Grant
October 14 2015 - 2:01AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
14 October 2015
For immediate release 14 October 2015
ANGLE plc ("the Company")
NEW PATENT GRANT
ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech
company, is pleased to announce that it has been granted a Canadian
patent for its Parsortix system, which captures rare cells in blood
for medical analysis.
The granted Canadian patent provides protection over a wide
range of uses of the Parsortix technology. Granted patents have
already been secured in the United States, China and Australia.
Corresponding patent applications have been made worldwide in
countries considered to represent substantial markets for Parsortix
products.
The Company is pursuing a strategy to strengthen the breadth and
duration of its patent coverage across major markets worldwide to
maximise the commercial returns that can be achieved from its
Parsortix technology. New patent applications will continue to be
made in all territories consistent with this strategy.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The grant of this patent in Canada further strengthens ANGLE's
IP position and maintains our momentum in expanding patent coverage
across major markets worldwide."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Russell Kerr, Olly Baxendale (Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, China and Australia and three
extensive families of patents are being progressed worldwide. The
system is based on a microfluidic device that captures cells based
on a combination of their size and compressibility. The Parsortix
system is established with strong positive evaluations from leading
cancer research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These Key Opinion Leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUOVRRVWARAAA
(END) Dow Jones Newswires
October 14, 2015 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024